Navidence didn’t show up to make noise. It showed up because real-world evidence has been loud for years and still unclear. Founded in 2022 and based in Aurora, Colorado, Navidence exists for a frustration everyone in clinical research knows and nobody has fixed. Data is everywhere. Trust is not. Definitions drift. Studies wobble. Regulators squint. The questions keep getting better. The tools don’t.
By headcount (about 25) and revenue (under $5M), Navidence looks early. That’s the wrong lens. It operates where scale usually fails, real-world data fractured across systems, studies, and standards. Navidence answers with precision. Its AI-native platform, RWE Sherpa, uses Computable Operational Definitions (CODefs) to turn ambiguity into something usable. Definitions humans can read and machines can execute. Evidence you can explain and evidence you can run, finally aligned.
That clarity pulled capital twice. In December 2025, Navidence closed a $3M seed led by Teamworthy Group. Eight weeks later, on January 27, 2026, Grand Ventures and Nina Capital co-led a second institutional seed round for an undisclosed amount. Different investors. Different geographies. Same read: real problem, right timing, credible early platform.
The team tells you why. Aaron Kamauu brings 15+ years of RWE across Roche, Parexel, and Anolinx. Matt Veatch adds decades from IQVIA and Syneos Health. Craig Parker anchors the tech with physician-level informatics depth. Amanda Shields brings research rigor to product. Andrew Ecob leads commercial motion. Michael Buck runs knowledge engineering with standards credibility regulators recognize.
Navidence isn’t trying to own data. It’s trying to define it. CODefs standardize populations, endpoints, and assumptions so studies stop arguing with themselves. A partnership with Nested Knowledge pulls literature directly into definition libraries. Less about speed. More about alignment. Teams move faster when fundamentals stop shifting.
The name fits. Navidence doesn’t promise a destination. It provides a map you can trust. As regulators push for reproducibility and sponsors demand confidence, investors like Grand Ventures and Nina Capital are betting the companies that define evidence will matter more than those that just store it.
